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screening. METHODS: A Markov model based on the natural
history of HPV and cervical cancer (CC) was developed to simu-
late transitions between health states (normal, HPV infection,
Cervical Intraepithelial Neoplasia (CIN) stages 1–3, CC stages
1–4, and death) in the presence of the current opportunistic
screening practices in Spain. The model was calibrated to Spanish
epidemiological endpoints: age-speciﬁc HPV and CIN preva-
lence, and age-speciﬁc CC incidence and mortality. Spanish data
was used to inform observed costs, screening and treatment
practices in Spain. Published efﬁcacy rates were used for the
HPV-16/18 vaccine including protection against non-vaccine
oncogenic HPV types (such as efﬁcacy against HPV-31 and -45).
RESULTS: Assuming the screening practices remain unchanged,
vaccinating all 12-year old girls would result in 79.1% and
79.5% decreases in the number of CC cases and deaths, respec-
tively. Vaccination would also produce substantial reductions in
the number of repeat screening tests due to abnormal cytology
and treatments for cervical dysplasia, which would partially
offset the cost of the vaccine. The introduction of Cervarix™ in
the current screening setting was predicted to result in an incre-
mental cost effectiveness ratio (ICER) of €31,749 per quality
adjusted life year (QALY) gained, when discounting at 3% for
costs and outcomes. Discounting at 4% for costs and 1.5% for
outcomes resulted in an ICER of €14,707 per QALY gained.
CONCLUSIONS: Universal vaccination with Cervarix™ for
12-year old girls within the current screening setting in Spain, is
predicted to be a cost-effective method of reducing precancerous
cervical lesions, cervical cancer incidence and mortality.
PIN13
ECONOMIC ANALYSIS OF MICAFUNGINVERSUS LIPOSOMAL
AMPHOTERICIN B FORTREATMENT OF CANDIDAEMIA AND
INVASIVE CANDIDIASIS IN ITALY
Viale P1, Sidhu M2, van Engen A3, Schoeman O3
1Policlinico Universitario di Udine, Udine, Italy, 2Astellas Pharma
Europe Ltd, Staines, UK, 3Quintiles Consulting, Hoofddorp,The
Netherlands
OBJECTIVES: To investigate the economic impact of introduc-
ing micafungin (MICA) for the treatment of systemic candida
infections (SCIs) (including invasive candidiasis and can-
didaemia) in Italy, a health economic analysis was performed
comparing MICA with liposomal amphotericin B (L-AMB).
METHODS: The model was based on data from a phase III,
randomised, double-blind trial comparing MICA with L-AMB.
The model entailed a period of 14–20 weeks from initiation of
treatment and was analysed from an Italian hospital perspective.
The analysis included hospitalisation and primary medication
costs. Unit costs of these resources were taken from Italian
costing sources. As the price for MICA was not available at the
time of analysis, the price per recommended daily dose (RDD) of
MICA (100 mg) was assumed to be equal to the price per RDD
of caspofungin (50 mg). The model endpoint was deﬁned as the
percentage of patients predicted to achieve complete or partial
clinical and mycological response after initial treatment, and be
alive after the 12-week follow-up period. The model was analy-
sed using cohort and second-order Monte Carlo (MC) simula-
tion. RESULTS: The analysis of this model shows that with
MICA 52.9% of patients were predicted to have treatment
success and survive 12 weeks after end of treatment compared
with 49.1% for L-AMB. MICA was predicted to be less expen-
sive than L-AMB costing €28,668 and €40,760 per patient,
respectively. Because of lower simulated costs and the higher
effectiveness of MICA (cost-effectiveness [C/E] ratio = €54,215)
compared with L-AMB (C/E ratio = €83,035), MICA dominates
L-AMB. The results of the MC simulation and sensitivity analy-
ses showed that MICA remained the most cost-effective option.
CONCLUSIONS: The lower costs and higher effectiveness pre-
dicted for MICA versus L-AMB in this analysis indicate that in
Italy, MICA is more cost-effective for the treatment of SCIs when
compared with L-AMB.
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OBJECTIVES: To simulate the treatment of nucleoside-naïve
HBe antigen negative CHB patients with entecavir or tenofovir
in the absence of head-to-head data for cost effectiveness com-
parison. METHODS: A hypothetical cohort of 1000 received
treatment with entecavir 0.5 mg or tenofovir 300 mg daily for
48 weeks. A patient level simulation model was developed to
estimate HBV DNA distributions, assuming a parametric dis-
tribution for baseline viral load (VL) and mean drop at 48
weeks, based on summary statistics from two RCTs; BMS
AI-463027 (entecavir) and GS 174-0102 (tenofovir). Efﬁcacy
outcomes were calibrated to the end points from both trials.
Liver complications over 10 years were projected using relative
risks for CHB progression for ﬁve HBV DNA categories
(R.E.V.E.A.L.-HBV epidemiology study). The Italian payer per-
spective was applied. Direct medical costs: drug acquisition,
associated physician visits, clinical monitoring, liver event man-
agement. All model inputs estimated from published data. Dis-
count rate: 3%. RESULTS: A simulation based on baseline VL
from the tenofovir trial, entecavir was superior to tenofovir in
mean serum HBV DNA reduction at 48 weeks, with drops of
5.0 vs 4.57 log10 copies/mL, leading to 97.8% and 91.1% of
patients reaching undetectable VL respectively. For 1000
patients, the projected number of HCC and DC events within
10 years were 36 and 5, and 71 and 13, for entecavir and
tenofovir respectively. Entecavir therapy was dominant, demon-
strating €934 saving in discounted lifetime medical costs and
QALY gain of 0.62 per patient. These estimates dropped to
€773 and 0.58 QALY respectively in a sensitivity analysis to
using the mean entecavir baseline VL, resulting in 90.1% and
82% of entecavir and tenofovir patients reaching undetectable
VL at 48 weeks respectively. CONCLUSIONS: In absence of
head-to-head data between the two agents, entecavir was pro-
jected to be a clinically and economically attractive alternative
to tenofovir in this patient population.
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OBJECTIVES: Viral bronchiolitis is the most frequent cause of
infection of the lower respiratory tract among children younger
than 12 months old, with frequent hospitalizations and rare
deaths. Palivizumab, a high cost drug, is approved for VSR
prophylaxis. Our objective was to assess the cost-effectiveness
of palivizumab in the prophylaxis of RSV bronchiolitis in high
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